145 related articles for article (PubMed ID: 30285881)
1. Surgical peritoneal stress creates a pro-metastatic niche promoting resistance to apoptosis via IL-8.
Pasquier J; Vidal F; Hoarau-Véchot J; Bonneau C; Daraï E; Touboul C; Rafii A
J Transl Med; 2018 Oct; 16(1):271. PubMed ID: 30285881
[TBL] [Abstract][Full Text] [Related]
2. Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.
He Y; Wu AC; Harrington BS; Davies CM; Wallace SJ; Adams MN; Palmer JS; Roche DK; Hollier BG; Westbrook TF; Hamidi H; Konecny GE; Winterhoff B; Chetty NP; Crandon AJ; Oliveira NB; Shannon CM; Tinker AV; Gilks CB; Coward JI; Lumley JW; Perrin LC; Armes JE; Hooper JD
Oncogene; 2016 Jan; 35(4):468-78. PubMed ID: 25893298
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of peritoneal cancer index in primary advanced ovarian cancer.
Llueca A; Escrig J;
Eur J Surg Oncol; 2018 Jan; 44(1):163-169. PubMed ID: 29198495
[TBL] [Abstract][Full Text] [Related]
4. Akt-activated endothelium promotes ovarian cancer proliferation through notch activation.
Hoarau-Véchot J; Touboul C; Halabi N; Blot-Dupin M; Lis R; Abi Khalil C; Rafii S; Rafii A; Pasquier J
J Transl Med; 2019 Jun; 17(1):194. PubMed ID: 31182109
[TBL] [Abstract][Full Text] [Related]
5. Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma.
Bonneau C; Rouzier R; Geyl C; Cortez A; Castela M; Lis R; Daraï E; Touboul C
Gynecol Oncol; 2015 Jan; 136(1):112-20. PubMed ID: 25449309
[TBL] [Abstract][Full Text] [Related]
6. Nobiletin (NOB) suppresses autophagic degradation via over-expressing AKT pathway and enhances apoptosis in multidrug-resistant SKOV3/TAX ovarian cancer cells.
Jiang YP; Guo H; Wang XB
Biomed Pharmacother; 2018 Jul; 103():29-37. PubMed ID: 29635125
[TBL] [Abstract][Full Text] [Related]
7. Positive peritoneal cytology at interval surgery is a poor prognostic factor in patients with stage T3c advanced ovarian carcinoma: A retrospective study.
Nagasaka K; Kawana K; Tomio K; Tsuruga T; Mori-Uchino M; Miura S; Tanikawa M; Miyamoto Y; Ikeda Y; Sone K; Adachi K; Matsumoto Y; Arimoto T; Oda K; Osuga Y; Fujii T
J Obstet Gynaecol Res; 2015 May; 41(5):755-62. PubMed ID: 25421004
[TBL] [Abstract][Full Text] [Related]
8. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.
Bai H; Li H; Li W; Gui T; Yang J; Cao D; Shen K
Oncotarget; 2015 Sep; 6(28):25520-32. PubMed ID: 26267321
[TBL] [Abstract][Full Text] [Related]
9. CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer.
Tjhay F; Motohara T; Tayama S; Narantuya D; Fujimoto K; Guo J; Sakaguchi I; Honda R; Tashiro H; Katabuchi H
Cancer Sci; 2015 Oct; 106(10):1421-8. PubMed ID: 26250934
[TBL] [Abstract][Full Text] [Related]
10. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
Asselin E; Mills GB; Tsang BK
Cancer Res; 2001 Mar; 61(5):1862-8. PubMed ID: 11280739
[TBL] [Abstract][Full Text] [Related]
11. Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells.
Kim SH; Juhnn YS; Song YS
Ann N Y Acad Sci; 2007 Jan; 1095():82-9. PubMed ID: 17404021
[TBL] [Abstract][Full Text] [Related]
12. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
13. GRO-α and IL-8 enhance ovarian cancer metastatic potential via the CXCR2-mediated TAK1/NFκB signaling cascade.
Yung MM; Tang HW; Cai PC; Leung TH; Ngu SF; Chan KK; Xu D; Yang H; Ngan HY; Chan DW
Theranostics; 2018; 8(5):1270-1285. PubMed ID: 29507619
[TBL] [Abstract][Full Text] [Related]
14. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
15. MiR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3.
Wu H; Xiao Z; Zhang H; Wang K; Liu W; Hao Q
Anticancer Drugs; 2014 Aug; 25(7):799-809. PubMed ID: 24686007
[TBL] [Abstract][Full Text] [Related]
16. Musashi-1 regulates AKT-derived IL-6 autocrinal/paracrinal malignancy and chemoresistance in glioblastoma.
Chen HY; Lin LT; Wang ML; Lee SH; Tsai ML; Tsai CC; Liu WH; Chen TC; Yang YP; Lee YY; Chang YL; Huang PI; Chen YW; Lo WL; Chiou SH; Chen MT
Oncotarget; 2016 Jul; 7(27):42485-42501. PubMed ID: 27285760
[TBL] [Abstract][Full Text] [Related]
17. Oxidative stress contributes to hepatocyte growth factor-dependent pro-senescence activity of ovarian cancer cells.
Mikuła-Pietrasik J; Uruski P; Pakuła M; Maksin K; Szubert S; Woźniak A; Naumowicz E; Szpurek D; Tykarski A; Książek K
Free Radic Biol Med; 2017 Sep; 110():270-279. PubMed ID: 28652056
[TBL] [Abstract][Full Text] [Related]
18. Senescent peritoneal mesothelium creates a niche for ovarian cancer metastases.
Mikuła-Pietrasik J; Uruski P; Sosińska P; Maksin K; Piotrowska-Kempisty H; Kucińska M; Murias M; Szubert S; Woźniak A; Szpurek D; Sajdak S; Piwocka K; Tykarski A; Książek K
Cell Death Dis; 2016 Dec; 7(12):e2565. PubMed ID: 28032864
[TBL] [Abstract][Full Text] [Related]
19. Akt-Activated Endothelium Increases Cancer Cell Proliferation and Resistance to Treatment in Ovarian Cancer Cell Organoids.
Hoarau-Véchot J; Blot-Dupin M; Pauly L; Touboul C; Rafii S; Rafii A; Pasquier J
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430649
[TBL] [Abstract][Full Text] [Related]
20. Combined inhibition of IL‑6 and IL‑8 pathways suppresses ovarian cancer cell viability and migration and tumor growth.
Zhang R; Roque DM; Reader J; Lin J
Int J Oncol; 2022 May; 60(5):. PubMed ID: 35315502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
